- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03068429
Fear Conditioned Response in Healthy Subjects and in OCD Patients Pre and Post Treatment With Sertraline. (FEARCON)
Fear Conditioning, Extinction and Recall in Healthy Subjects and in Obsessive-compulsive Disorder Patients Pre and Post Treatment With Sertraline.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Fear conditioning paradigms are used to investigate the learning process of the fear response in patients with psychiatric disorders and healthy subjects. Patients with post traumatic stress disorder have been shown to fail to retrieve the memory of fear extinction during the recall phase of the fear conditioning paradigm when compared to healthy subjects. In one previous trial, obsessive-compulsive disorder (OCD) patients have demonstrated the same failure to recall extinction and the results from functional magnetic resonance imaging (fMRI) activation maps have shown different regions being recruited during recall when compared with healthy subjects. However, in that previous trial, some of the OCD patients included were already taking medication for OCD. In the current trial, we will evaluate 24 unmedicated OCD patients with a two-day fear conditioning paradigm before and after 4-weeks of treatment initiation with sertraline up to 200mg/day or maximum tolerated dosage. Sertraline is a first-line treatment option for OCD. At baseline, OCD patients will be compared to 24 healthy subjects. At post treatment, fear conditioning and fMRI results wil be compared to baseline. OCD patients are expected to demonstrate worsened extinction retention compared to healthy subjects at baseline. Sertraline treatment is expected to improve extinction retention compared to baseline and to normalize the brain regions being recruited with the conditioned stimuli presented during the recall phase. By "normalize" we mean that after treatment the regions being recruited will be the same as the ones recruited by healthy subjects during baseline, in other words, differences found at baseline regarding brain activation by the conditioned stimuli are expected to disappear after treatment.
Abbreviations: CS= conditioned stimuli, CS+= conditioned stimuli to shock, CS-=neutral conditioned stimuli, CS+E= extinguished conditioned stimuli to shock, CS+U=unextinguished conditioned stimuli to shock
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Sao Paulo, Brazil, 05403-010
- Institute of Psychiatry, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Healthy controls
-willingness to participate in research
OCD patients
- willingness to participate in research
- main diagnosis of OCD (psychiatric clinical evaluation)
- minimum YBOCS (Yale Brown Obsessive-compulsive severity scale) score of 16 points
Exclusion Criteria:
Healthy controls
- any current psychiatric diagnosis according to evaluation using semi structured interview for DSM IV diagnoses (SCID I)
- any past psychiatric diagnoses except single major depression episode and simple phobia (evaluation by semi structure interview-SCID I)
- current use of psychotropic medications (last use has to be at least 3 months prior to study initiation)
- chronic use of any medications except vitamins and contraceptives
- MRI exclusionary criteria (metal implants, recently made tatoos, claustrophobia, etc)
- being pregnant
OCD patients
- comorbidity with neurodevelopmental disorders (autism, mental retardation), current psychotic disorders, current substance dependence or abuse, bipolar mood disorder according to evaluation using semi structured interview for DSM IV diagnoses (SCID I)
- current use of psychotropic medications (last use has to be at least 3 months prior to study initiation)
- MRI exclusion criteria(metal implants, recently made tatoos, claustrophobia, etc)
- being pregnant or at risk of becoming pregnant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sertraline open label
Sertraline hydrochloride up to 200mg/day or maximum tolerated dosage for 4-weeks.
|
first week: sertraline hydrochloride 50mg/day, second week: sertraline hydrochloride 100mg/day, third week: sertraline hydrochloride 150mg/day, fourth week: sertraline hydrochloride 200mg/day OBS.: Other SSRIs (fluoxetine, paroxetine, escitalopram) with equivalent dosage schedules can be used if patients report prior intolerance to sertraline
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Main behavioral measure (extinction retention index)
Time Frame: Baseline for both groups (OCD and helthy subjects), change from baseline to 4 weeks after treatment initiation only for intervention group
|
Equation: 100-((MEAN(2 first CS+E during recall)/MAXIMUM(2 last CS+E during extinction))*100)
|
Baseline for both groups (OCD and helthy subjects), change from baseline to 4 weeks after treatment initiation only for intervention group
|
Main functional neuroimaging measure
Time Frame: Baseline for both groups (OCD and helthy subjects), change from baseline to 4 weeks after treatment initiation only for intervention group
|
ventro medial prefrontal cortex (vmPFC) activation during recall phase
|
Baseline for both groups (OCD and helthy subjects), change from baseline to 4 weeks after treatment initiation only for intervention group
|
Main treatment outcome measure
Time Frame: Change from baseline to 4 weeks after treatment initiation (only interventional group)
|
Yale Brown Obsessive Compulsive Scale reduction (final score minus initial score)
|
Change from baseline to 4 weeks after treatment initiation (only interventional group)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Main behavioral measure baseline comparison (extinction retention index OCD patients versus healthy subjects)
Time Frame: Baseline
|
Equation: 100-((MEAN(2 first CS+E during recall)/MAXIMUM(2 last CS+E during extinction))*100)
|
Baseline
|
Main functional neuroimaging measure (activation maps for contrast CS+E versus CS-during recall phase,OCD patients versus healthy subjects)
Time Frame: Baseline (all subjects)
|
ventro medial prefrontal cortex (vmPFC) activation during recall phase
|
Baseline (all subjects)
|
Secondary behavioral measure (learning- conditioning index, OCD patients pre and post treatment)
Time Frame: Change from baseline to 4 weeks after treatment initiation (only interventional group)
|
Equation: MEAN(all CS+ during conditioning)-MEAN(all CS- during conditioning)
|
Change from baseline to 4 weeks after treatment initiation (only interventional group)
|
Secondary behavioral measure (learning- conditioning index, OCD patients versus healthy subjects)
Time Frame: Baseline (all subjects)
|
Equation: MEAN(all CS+ during conditioning)-MEAN(all CS- during conditioning)
|
Baseline (all subjects)
|
Secondary Behavioral Measure (context discrimination index based on skin conductance, OCD patients pre and post treatment)
Time Frame: Change from baseline to 4 weeks after treatment initiation (only interventional group)
|
Equation: MEAN(first two CS+U during renewal)-MEAN(first two CS+U during recall)
|
Change from baseline to 4 weeks after treatment initiation (only interventional group)
|
Secondary Behavioral Measure (context discrimination index based on skin conductance, OCD patients versus healthy subjects)
Time Frame: Baseline (all subjects)
|
Equation: MEAN(first two CS+U during renewal)-MEAN(first two CS+U during recall)
|
Baseline (all subjects)
|
Secondary functional neuroimaging measure (functional activation maps for contrast CS+/CS- during conditioning phase, OCD patients pre and post treatment)
Time Frame: Change from baseline to 4 weeks after treatment initiation (only interventional group)
|
Gain in amygdala activation during conditioning for CS+ presentations
|
Change from baseline to 4 weeks after treatment initiation (only interventional group)
|
Secondary functional neuroimaging measure (functional activation maps for contrast CS+/CS- during conditioning phase, OCD patients versus healthy subjects)
Time Frame: Baseline (all subjects)
|
Gain in amygdala activation during conditioning for CS+ presentations
|
Baseline (all subjects)
|
Secondary functional neuroimaging measure (functional activation maps for contrast CS+E/CS- during recall phase of baseline measurement, OCD patients versus healthy subjects)
Time Frame: Baseline (all subjects)
|
Alternative activations (OCD patients versus controls), regions other than the vmPFC, activated with CS+ presentations during recall
|
Baseline (all subjects)
|
Secondary functional neuroimaging measure (functional activation maps for contrast CS+E/CS- during recall phase comparing change between post and pre treatment)
Time Frame: Change between baseline and 4 weeks after treatment initiation (only interventional group)
|
Alternative activations (OCD patients post treatment compared with baseline), regions other than the vmPFC, activated with CS+E presentations during recall
|
Change between baseline and 4 weeks after treatment initiation (only interventional group)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Juliana B Diniz, MD, PhD, Researcher
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Personality Disorders
- Anxiety Disorders
- Compulsive Personality Disorder
- Obsessive-Compulsive Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Sertraline
Other Study ID Numbers
- 0182/11
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Statistical Analysis Plan (SAP)
- Analytic Code
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obsessive-Compulsive Disorder
-
Anne Katrine PagsbergCopenhagen Trial Unit, Center for Clinical Intervention Research; Danish Research...Active, not recruitingObsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in AdolescenceDenmark
-
Baylor College of MedicineRecruitingObsessive-Compulsive Disorder | Cognitive Behavioral Therapy | Obsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in AdolescenceUnited States
-
Stanford UniversityCompletedObsessive Compulsive DisorderUnited States
-
NYU Langone HealthCompletedObsessive Compulsive DisorderUnited States
-
Massachusetts General HospitalActive, not recruitingObsessive Compulsive DisorderUnited States
-
Boston University Charles River CampusCompletedObsessive Compulsive DisorderUnited States
-
Butler HospitalNational Institute of Mental Health (NIMH)CompletedObsessive Compulsive DisorderUnited States
-
Karolinska InstitutetCompletedObsessive Compulsive DisorderSweden
-
Roseli ShavittCompleted
-
University of South FloridaMassachusetts General HospitalCompletedObsessive-compulsive DisorderUnited States
Clinical Trials on Sertraline Hydrochloride
-
University of PittsburghCompleted
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
Torrent Pharmaceuticals LimitedCompleted
-
Torrent Pharmaceuticals LimitedCompleted
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedDepression | Panic Disorder
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedDepression | Panic Disorder
-
Beijing HuiLongGuan HospitalCompleted